UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The discovery of factor X: a personal reminiscence

Thrombosis and haemostasis, 2007-07, Vol.98 (1), p.16-19

Bachmann, Fedor

2007

Volltextzugriff (PDF)

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes

Journal of the American College of Cardiology, 2012-04, Vol.59 (16), p.1413-1425

2012

Volltextzugriff (PDF)

Vitamin K antagonists in heart disease: Current status and perspectives (Section III): Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease

Thrombosis and haemostasis, 2013-12, Vol.110 (12), p.1087-1107

2013

Volltextzugriff (PDF)

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

Thrombosis and haemostasis, 2014, Vol.111 (5), p.781-782

2014

Volltextzugriff (PDF)

Plasminogen activator expression in human atherosclerotic lesions

Arteriosclerosis, thrombosis, and vascular biology, 1995-09, Vol.15 (9), p.1444-1455

1995

Volltextzugriff (PDF)

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

Thrombosis and haemostasis, 2013-04, Vol.109 (4), p.569-579

2013

Volltextzugriff (PDF)

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease Position Paper

Journal of the American College of Cardiology, 2012-04, Vol.59 (16), p.1413-1425

2012

Volltextzugriff (PDF)

Expert consensus document on the use of antiplatelet agents: The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

European heart journal, 2004, Vol.25 (2), p.166-181

2004

Volltextzugriff (PDF)

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

Thrombosis and haemostasis, 2016-04, Vol.115 (4), p.685-711

2016

Volltextzugriff (PDF)

Anticoagulants in heart disease: current status and perspectives

European heart journal, 2007-04, Vol.28 (7), p.880-913

2007

Volltextzugriff (PDF)

Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease

Thrombosis and haemostasis, 2013-05, Vol.109 (5), p.769-786

2013

Volltextzugriff (PDF)

Plasminogen activator inhibitor 1: a new prognostic marker in septic shock

Thrombosis and haemostasis, 1989, Vol.61 (3), p.459-462

1989

Volltextzugriff (PDF)

Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states

Thrombosis and haemostasis, 1988, Vol.59 (1), p.7-12

1988

Volltextzugriff (PDF)

Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects

Seminars in thrombosis and hemostasis, 1999, Vol.25 Suppl 2, p.15-19

1999

Volltextzugriff (PDF)

Laboratory monitoring of low‐molecular‐weight heparin therapy

Journal of thrombosis and haemostasis, 2004-06, Vol.2 (6), p.1003-1003

Hirsh, J.

2004

Volltextzugriff (PDF)

Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma

Blood, 1993-11, Vol.82 (10), p.2937-2942

1993

Volltextzugriff (PDF)

The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase

Thrombosis and haemostasis, 1986, Vol.55 (1), p.65-69

1986

Volltextzugriff (PDF)

Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios

Revista española de cardiologia, 2004, Vol.57 (10), p.963-980

2004

Volltextzugriff (PDF)

Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries

Arteriosclerosis and thrombosis, 1993-07, Vol.13 (7), p.1090-1100

1993

Volltextzugriff (PDF)

STUDIES ON THE BINDING OF TISSUE PLASMINOGEN ACTIVATOR TO FIBRINOGEN AND FIBRIN

Recent biochemical and medical aspects, 2019, Vol.1, p.377-388

Originally published 1982, 2019

Volltextzugriff (PDF)

Système du plasminogène et son exploration

EMC - Hématologie, 2006-01, Vol.1 (1), p.1-18

2006

Volltextzugriff (PDF)

Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders

Oncogene, 1995-02, Vol.10 (3), p.523-528

1995

Volltextzugriff (PDF)

Plasminogen Activator Inhibitor 1: Development of a Radioimmunoassay and Observations on Its Plasma Concentration During Venous Occlusion and After Platelet Aggregation

Blood, 1987-11, Vol.70 (5), p.1645-1653

1987

Volltextzugriff (PDF)

Expert consensus document on the use of antiplatelet agents

Revista española de cardiologia, 2004-10, Vol.57 (10), p.963-980

2004

Volltextzugriff (PDF)

Frequent Detection of Epstein-Barr Virus DNA by the Polymerase Chain Reaction in Lymph Node Biopsies From Patients With Hodgkin's Disease Without Genomic Evidence of B- or T-Cell Clonality

Blood, 1991-08, Vol.78 (3), p.760-767

1991

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(90)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(57)
Science & Technology
(47)
Life Sciences & Biomedicine
(46)
Biological And Medical Sciences
(36)
Medical Sciences
(30)
Hematology
(28)
Cardiovascular System & Cardiology
(23)
Peripheral Vascular Disease
(17)
Female
(15)
High Energy Physics - Experiment
(15)
Male
(15)
Physics
(15)
Hematologic And Hematopoietic Diseases
(14)
Adult
(13)
Middle Aged
(11)
Cardiology. Vascular System
(10)
Fundamental And Applied Biological Sciences. Psychology
(10)
Animals
(9)
Blood Coagulation. Blood Cells
(9)
Fibrinolysis
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The discovery of factor X: a personal reminiscence

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes

Vitamin K antagonists in heart disease: Current status and perspectives (Section III): Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

Plasminogen activator expression in human atherosclerotic lesions

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease Position Paper

Expert consensus document on the use of antiplatelet agents: The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

Anticoagulants in heart disease: current status and perspectives

Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease

Plasminogen activator inhibitor 1: a new prognostic marker in septic shock

Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states

Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects

Laboratory monitoring of low‐molecular‐weight heparin therapy

Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma

The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase

Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios

Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries

STUDIES ON THE BINDING OF TISSUE PLASMINOGEN ACTIVATOR TO FIBRINOGEN AND FIBRIN

Système du plasminogène et son exploration

Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders

Plasminogen Activator Inhibitor 1: Development of a Radioimmunoassay and Observations on Its Plasma Concentration During Venous Occlusion and After Platelet Aggregation

Expert consensus document on the use of antiplatelet agents

Frequent Detection of Epstein-Barr Virus DNA by the Polymerase Chain Reaction in Lymph Node Biopsies From Patients With Hodgkin's Disease Without Genomic Evidence of B- or T-Cell Clonality

Suchergebnisse filtern